Preview

PDF Pending copyright assessment - Request a copy 985Kb

There are over 28 million CpG sites in the human genome. Assessing the methylation status of each of these sites will be required to understand fully the role of DNA methylation in health and disease. Genome-wide analysis, using arrays and high-throughput sequencing, has enabled assessment of large fractions of the methylome, but each protocol comes with unique advantages and disadvantages. Notably, except for whole-genome bisul- fite sequencing, most commonly used genome-wide methods detect <5% of all CpG sites. Here, we discuss approaches for methylome studies and compare genome coverage of promoters, genes, and intergenic regions, and capacity to quantitate individual CpG methylation states. Finally, we examine the extent of published cancer methylomes that have been generated using genome-wide approaches.

Item Type:	Substantial Review
Keywords:	DNA methylation, next-generation sequencing, cancer methylomes
Research Division:	Biological Sciences
Research Group:	Genetics
Research Field:	Epigenetics (incl. genome methylation and epigenomics)
Objective Division:	Health
Objective Group:	Clinical health
Objective Field:	Clinical health not elsewhere classified
UTAS Author:	Taberlay, PC (Associate Professor Phillippa Taberlay)
ID Code:	101258
Year Published:	2014
Web of Science® Times Cited:	121
Deposited By:	Medicine
Deposited On:	2015-06-15
Last Modified:	2015-07-06
Downloads:	0